Health & Wellness

Press Releases

Dr. Angela Alistar, National Leader in Gastrointestinal Cancer Research, to Speak at International Oncology Conference

0a1ff70873c63771b015_Dr._Angela_Alistar_2017.jpg
0a1ff70873c63771b015_Dr._Angela_Alistar_2017.jpg

Nationally renowned gastrointestinal (GI) cancer researcher Angela Alistar, MD, medical director of GI medical oncology at Morristown Medical Center, Atlantic Health System Cancer Care, has been invited to speak this week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics:  Discovery, Biology, and Clinical Applications.

The conference will be held in Philadelphia October 26-30, and is sponsored by the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC). It is considered the premier international meeting on novel cancer therapeutics. 

Dr. Alistar will speak on cancer metabolism and her pioneering study, published this summer in The Lancet Oncology, on CPI-613, an advanced, first-in-class drug that offers new hope for people with pancreatic cancer, one of the most difficult cancers to treat.  Her presentation will take place on October 28 at 4:30 p.m. ET, as part of a session on cancer metabolism chaired by Dr. Dimitrios Anastasiou from London’s Francis Crick Institute and Dr. W. Marston Lineham, from the NCI.

Sign Up for E-News

“It is truly a great honor to be invited to speak at this meeting, along with this stellar lineup of internationally renowned cancer researchers,” said Dr. Alistar.  “I look forward to sharing the promise my studies have shown, and to discussing future research plans.”

Dr. Alistar will serve as the Co-Principal Investigator with Dr. Philip Philip of Karmanos Cancer Institute on a planned multi-center Phase III study of CPI-613 in combination with modified FOLFIRINOX, a multidrug treatment for metastatic pancreatic cancer.  She has led four other clinical trials of CPI-613 for GI cancers, as well as studies of other novel oncology drugs, and research to determine disease processes and genetic factors in cancers of the gastrointestinal tract. 

Pancreatic cancer is the third leading cause of cancer-related death in the United States, with a five-year survival rate of just seven percent.  Fifty-three percent of patients are diagnosed with advanced disease. *

“We are extremely proud of the fact that Dr. Alistar has been invited to share her groundbreaking clinical research at this distinguished international symposium,” said Eric Whitman, MD, medical director, Atlantic Health System Cancer Care. “She has continued to design and develop innovative cancer treatments since joining Atlantic Medical Group Oncology. We are pleased that our growing team of outstanding and compassionate physicians is able to offer patients in this community access to the latest treatment advances through clinical trials across a broad range of cancer types."

Dr. Alistar joined Atlantic Health System earlier this year from the Wake Forest School of Medicine, where she led the GI oncology team, bringing cutting-edge treatments to patients. While there, she designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials. She was the Principal Investigator at Wake Forest University of the Precision Oncology study, which is poised to generate new hypotheses in the era of genomic driven clinical trials.

Study of Pancreatic Cancer Drug Provides Hope for Difficult-to-Treat Patients 

In the recent Lancet Oncology study, Dr. Alistar and colleagues conducted a Phase I clinical trial of CPI-613, in combination with a modified version of FOLFIRINOX, a current multidrug treatment regimen approved by the FDA for use in pancreatic cancer that has spread beyond the pancreas.  The trial was designed to determine the maximum tolerated dose of CPI-613 when used in combination with the modified FOLFIRINOX regimen in patients with Stage IV pancreatic cancer.  The study provided preliminary evidence of the drug combination’s efficacy, as well as demonstrating its safety and tolerability.

CPI-613, developed by New Jersey-based Rafael Pharmaceuticals, is a new type of medication known as an altered energy metabolism directed (AEMD) drug.  It is the first anticancer drug of its kind.  It is designed to disrupt the altered energy production pathways in cancer cells by selectively targeting a process in cell multiplication and survival. 

Background on Dr. Alistar

Dr. Alistar’s primary focus at Wake Forest School of Medicine was on immuno-oncology and its application in treatment of gastrointestinal cancers of the pancreas, colon, rectum, bile duct and esophagus, as well as in treating melanoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genetics. An assistant professor of internal medicine at Wake Forest before joining Atlantic Health, she was also a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds Committee, and the Hepatobiliary Oncology Committee. She is a member of the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many other professional societies. She also serves as a member and advisor to several other health care organizations.  She is certified by the American Board of Internal Medicine, in both internal medicine and medical oncology.

Dr. Alistar received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania, and conducted her internship and residency at Englewood Hospital and Medical Center, where she was chief resident. After her residency, she was a fellow in hematology and medical oncology at Mount Sinai School of Medicine, Tisch Cancer Institute. She currently serves as an ad hoc reviewer for JAMA and was recently the recipient of the Danny Danielson Translational Innovation Award for her dedication to clinical research.

Dr. Alistar is a physician with Atlantic Hematology Oncology at the Carol G. Simon Cancer Center -Morristown Medical Center campus.  She is affiliated with Atlantic Medical Group, and is a participating provider in the Atlantic Accountable Care Organization. Dr. Alistar can be reached at 973-971-7111

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Roxbury

Upcoming Events

Carousel_image_7abaddd12cc7c9e9e960_u18-usa-fistball-world-championships-768x439

Mon, July 16, 8:00 AM

Horseshoe Lake Park, Succasunna

2018 U18 Fistball World Championships

Sports

Carousel_image_1935cc3c3e1eb0a13281_vbs_2018_rolling_river_rampage

Mon, July 16, 9:00 AM

Succasunna United Methodist Church , Succasunna

Vacation Bible School

Religions And Spirituality

Carousel_image_1b0a2f207b81222740c4_caeb94737438cbc9ce85_garden-302259_640

Tue, July 17, 6:30 AM

Roxbury Public Library, Succasunna, NJ 07876

CREATING A COTTAGE STYLE GARDEN

Education Home & Garden

Carousel_image_879477a3476e088cc8e2_st_moritz

Tue, July 17, 6:00 PM

St. Moritz Grill & Bar, Sparta

St. Moritz Dinner, Retirement Income Workshop

Business & Finance

Have You Seen Buttons?

July 11, 2018

MOUNT OLIVE, NJ - Residents of Roxbury living near Flanders are asked to keep an eye out for a lost female Yorkie mix that has been missing since July 7.

"Buttons" was last seen near Kevin Drive and Christopher Court in Flanders. The dog, described as friendly but shy, is brown with dark highlights and a white chest patch. If you see her, please call 973-219-9323.

Columns

Peyton Knight's Pointers for Safer Driving

Many customers ask my advice for ways to add more years of life to their vehicles. Here are a few pointers from my 35 years of experience in the auto repair industry, as well as some tips to keep you safer on the road.  

1.    Pull Through a Parking Spot.  Pull through to the other side of a parking space so your vehicle faces forward out ...

More Snow! Let Your Kid Drive in It!

ROXBURY, NJ - We are again about to be walloped by a snowstorm. These words, first written at the beginning of winter, need to be reiterated:

Many parents with a new driver at home will see the storm approaching and instinctively decide to not allow their kids to get behind the wheel until the snow's been cleared.

They might want to rethink that.

When it snows, ...

Is Your Car Ready for Old Man Winter?

You know it’s coming: That first frigid morning when you discover your car is covered in ice. Old Man Winter has reared his ugly head once again to wreak havoc on your car and your ride to work. 

Well, I’ve got one thing to say about that: Let’s be ready for him this year!

Owning a repair shop for over 30 years, I have spent many harsh winters coaxing a dead ...

AtlantiCast

AtlantiCast Episode 17

On this week’s AtlantiCast, it’s National Men’s Health Month, so check out important health tips for you or the men in your life, learn about groundbreaking research into breast cancer treatment that could mean an end to chemotherapy for some patients, meet a local sports hero who’s living his baseball dreams thanks to Goryeb Children’s Hospital and much ...

AtlantiCast: Episode 16

Summer is in the air, and the latest episode of AtlantiCast is ready to help you enjoy some fun outdoors while staying safe! This week’s episode opens with tips for sunscreen usage from Atlantic Health System’s Chief Medical and Academic Officer, Dr. Jan Schwarz-Miller. You’ll also learn about how Atlantic Health System is advancing the future of health care through ...

Letters to TAPinto Roxbury

'Housekeeping Guides and Landscape Respect' a Must for Roxbury

July 2, 2018

Dear TAPinto Roxbury,

Nice to see your coverage of the plans to improve visual image of Landing.  

In the meantime the DPW or Road Department is storing materials on Shippenport Road in such a manner that it looks like illegal dumping. And that is nothing compared to the ugly problem on area used by contractors (?) next to Route 80 ramp by Frontage Road.

If we are ...

Warsaw of Ledgewood Makes St. Lawrence Dean's List

July 2, 2018

CANTON, NY - Nolan Warsaw of Ledgewood has been selected for inclusion on St. Lawrence University's Dean's List for academic achievement during the Spring 2018 semester.

Warsaw is a member of the Class of 2021. Warsaw attended Roxbury High School.

To be eligible for the Dean's List, a student must have completed at least four courses and have an academic average of 3.6 based on ...

Two From Roxbury Graduate From Roger Williams

BRISTOL, RI - The following local residents were among the 1,127 students who received their degrees in May as part of the Class of 2018

Paul Bohrer of Succasunna N, with a B.A. in Public Health

Samuel Sherwood of Succasunna NJ (07876), with a B.S. in Finance

Fleming Chosen to Represent RHS at Annual NJ HOBY Seminar

ROXBURY, NJ - Roxbury High School sophomore Allison Fleming from Succasunna represented Roxbury High School at this year’s annual NJ Hugh O’Brian Youth (HOBY) Leadership Seminar.

Fleming spent three days in June at Kean University with more than 300 other sophomores from around the state.

Founded in 1958, HOBY’s mission is to inspire and develop our global ...

Press Releases

Roxbury BOYS & GIRLS INVITED TO FREE SUMMER ADVENTURE NIGHTS

July 13, 2018

Events Will Include STEM, Shooting sports, games and More!

_____________________________

STANHOPE, NJ – July 5, 2018– Time for the whole family to experience adventure this summer!  Have some free summer evenings and ready for a summer evening of family fun?!  Families are invited to attend any of four Family Adventure Nights at Camp Wheeler or Watchung Day Camp at no ...

Take the 2018 TAPinto Reader Survey

How often do you read TAPinto?  Have you downloaded the TAPinto APP?  These are a few of the questions for readers in our 2018 TAPinto Reader Survey.

We want to hear from you!

The survey will take less than five minutes to complete and will help TAPinto better serve you. 

Take the 2018 TAPinto Reader Survey.

Thank you.  We appreciate your support and ...